Abstract 280P
Background
Phosphatidylinositide-3-kinase (PI3K) regulates proliferation and apoptosis and; somatic PIK3CA-mutations may activate these processes. In a prospective cohort study of early breast cancer (eBC) patients, in case of somatic PIK3CA-mutation we observed resistance to aromatase inhibitor (AI) therapy (Reinhardt K et al., Breast Cancer Res Treat 2022 ;196:483–493). This study is aimed at validating these findings in a second cohort.
Methods
We studied a unicentre cohort of 262 patients with steroid hormone receptor-positive, HER2-negative eBC, who were planed to be treated with endocrine therapy only: aromatase inhibitor (AI, n=183) or Tamoxifen (TAM, n=69), AI and TAM (n=9), Fulvestrant (n=1) and tested the three most common somatic PIK3CA gene mutations (H1047R, E545K, E542K) by qPCR. The primary endpoint was recurrence-free survival (RFS), secondary endpoint overall survival (OS). Median follow up was 62 months.
Results
The PIK3CA-mutation rate was 42% (110 of 262). Overall, there was no difference considering RFS between patients with AI (n=183) and TAM (n=69) therapy (5 yrs-RFS 91.7% in both groups). Patients of the AI group harbouring a somatic PIK3CA mutation (n=75) had non-significantly more RFS related events compared to patients with PIK3CA wildtype (n=108): 5 yrs-RFS 89.5% (95% CI 82.1-97.0) versus 93.2% (95%CI 87.9 - 98.5), respectively (HR=1.2, 95%CI 0.461-2.961; n.s.). After 5 yrs, 91.2% (95% CI 84.5 – 97.9) of the patients with PIK3CA mutation were alive and 94.4% (95% CI 89.7 – 99.1) of patients without PIK3CA mutation, respectively (HR=1.3, 95% CI 0.453-3.447; n.s.). In the group of patients who were treated with TAM only (n=69), no interaction was observed between PIK3CA mutation and RFS or OS, respectively.
Conclusions
Although we observed a trend that AIs are less effective in patients with PIK3CA mutated tumours, formal validation is still lacking. Further data including prospective studies are required.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Thomssen: Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, Aurikamed, Daiichi Sankyo, Gilead, Jörg Eickeler, Hexal, Lilly, Medupdate, MSD, Nanostring, Novartis, Onkowiisen, Pfizer, Roche, Seagen, Vifor; Financial Interests, Personal, Financially compensated role: Forum Sanitas; Non-Financial Interests, Personal, Member: AGO Breast committee, ASCO, DGGG, DGS, DKG, EORTC; Non-Financial Interests, Personal, Member of Board of Directors: AGO-B Breast Study Group; Non-Financial Interests, Personal, Officer: BIG; Non-Financial Interests, Personal, Invited Speaker: ESO; Non-Financial Interests, Personal, Steering Committee Member: ESMO. All other authors have declared no conflicts of interest.
Resources from the same session
334P - The contribution of nurses in early detection of breast cancer in Cameroon
Presenter: Ngalla Calvin
Session: Poster session 02
335P - Real-world data: Correlation of radiological and pathologic complete response after neoadjuvant treatment of breast cancer
Presenter: Katarina Cular
Session: Poster session 02
336P - Dual-mode near-infrared multispectral imaging system equipped with deep learning models improves the identification of cancer foci in breast cancer specimens
Presenter: Yueping Liu
Session: Poster session 02
337P - Comparison of fused diffusion-weighted imaging using unenhanced MRI and abbreviated post-contrast-enhanced MRI in patients with breast cancer
Presenter: Kyeyoung Lee
Session: Poster session 02